Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27851852)
Watch
English
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
22805291
retrieved
13 November 2016
title
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
(English)
1 reference
stated in
PubMed
PubMed ID
22805291
retrieved
13 November 2016
main subject
phase I clinical trial
0 references
pharmacodynamics
1 reference
based on heuristic
inferred from title
pharmacokinetics
1 reference
based on heuristic
inferred from title
author
Razelle Kurzrock
series ordinal
16
object named as
Razelle Kurzrock
0 references
Keith Flaherty
series ordinal
17
object named as
Keith Flaherty
0 references
Jeffrey R Infante
series ordinal
1
object named as
Jeffrey R Infante
0 references
Vijay G R Peddareddigari
series ordinal
11
object named as
Vijay G R Peddareddigari
0 references
Leslie A Fecher
series ordinal
2
object named as
Leslie A Fecher
0 references
Douglas J DeMarini
series ordinal
7
object named as
Douglas J DeMarini
0 references
Howard A Burris
series ordinal
18
object named as
Howard A Burris
0 references
Ngocdiep T Le
series ordinal
12
object named as
Ngocdiep T Le
0 references
author name string
Gerald S Falchook
series ordinal
3
0 references
Sujatha Nallapareddy
series ordinal
4
0 references
Michael S Gordon
series ordinal
5
0 references
Carlos Becerra
series ordinal
6
0 references
Donna S Cox
series ordinal
8
0 references
Yanmei Xu
series ordinal
9
0 references
Shannon R Morris
series ordinal
10
0 references
Lowell Hart
series ordinal
13
0 references
Johanna C Bendell
series ordinal
14
0 references
Gail Eckhardt
series ordinal
15
0 references
Wells A Messersmith
series ordinal
19
0 references
language of work or name
English
1 reference
based on heuristic
inferred from title
publication date
August 2012
0 references
published in
Lancet Oncology Commission
0 references
volume
13
0 references
issue
8
0 references
page(s)
773-81
0 references
cites work
Development of anticancer drugs targeting the MAP kinase pathway
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A synthetic inhibitor of the mitogen-activated protein kinase cascade
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
MAP kinase pathway signalling is essential for extracellular matrix determined mammary epithelial cell survival
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
BRAF mutation predicts sensitivity to MEK inhibition
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Accelerated titration designs for phase I clinical trials in oncology
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1470-2045(12)70270-X
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
549078
OpenCitations bibliographic resource ID
549078
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
549078
PubMed ID
22805291
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
549078
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
